CLAIMS

1. Use of a composition in the manufacture of a medicament for the treatment of asthma in a subject at risk of asthma exacerbation, wherein the composition comprises therapeutically effective amounts of albuterol and budesonide, and wherein the composition is configured to be administered via a metered dose inhaler,

wherein the composition reduces risk of severe asthma exacerbation by at least about 15% as compared to a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation.

2. The use of claim 1, wherein:

(i) the composition reduces risk of severe asthma exacerbation in the subject by at least about 20% or at least about 25%, as compared to a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation;

(ii) a hazard ratio of the composition as compared to a composition comprising a same dose of albuterol alone is less than about 0.9, less than about 0.8, or less than about 0.7;

(iii) the composition provides at least about 20% lower or at least about 25% lower annualized severe asthma exacerbation rate in the subject as compared with a composition comprising a same dose of albuterol alone;

(iv) the composition reduces the subject's number of severe asthma exacerbations requiring hospitalization by at least 30% as compared to a composition comprising a same dose of albuterol alone;

(v) the composition reduces the subject's number of severe asthma exacerbations requiring emergency and/or urgent care by at least 20% as compared to a composition comprising a same dose of albuterol alone;

(vi) the composition reduces the subject's annualized total systemic corticosteroid dose by at least 30% as compared to a composition comprising a same dose of albuterol alone; or

(vii) any combination of (i)-(vi).

3. The use of claim 1 or 2, wherein:

(i) the subject's forced expiratory volume in 1 second area under the curve from 0-6 hours (FEV_1 AUC_{0-6}) at 12 weeks following administration of the composition is greater than 110 mL;

(ii) the subject's FEV_1 AUC_{0-6} at 12 weeks following administration of the composition is at least 10% higher as compared to a subject administered with a same dose of albuterol alone or a same dose of budesonide alone;

(iii) the subject's trough FEV_1 at 12 weeks following administration of the composition is greater than 90 mL;

(iv) the subject's trough FEV_1 at 12 weeks following administration of the composition is at least 10% higher as compared to a subject administered with a composition comprising a same dose of albuterol alone or a same dose of budesonide alone; or

(v) any combination of (i)-(iv).

4. The use of any one of claims 1 to 3, wherein the composition is configured to be administered by delivery of one or more metered doses from the metered dose inhaler, wherein about 100 to about 300 μg, or about 120 to about 250 μg, or about 150 to about 200 μg, or about 180 μg albuterol is delivered; and about 25 to about 250 μg, or about 50 to about 200 μg, or about 75 to about 175 μg, or about 80 or about 160 μg budesonide is delivered.

5. The use of any one of claims 1 to 4, wherein about 150 to about 200 μg albuterol and about 75 to about 175 μg budesonide are delivered, or about 180 μg albuterol and about 80 or about 160 μg budesonide are delivered.

6. The use of any one of claims 1 to 5, wherein the composition is configured to be administered by delivery of two metered doses from the metered dose inhaler, wherein each delivered dose comprises about 60 to about 125 μg albuterol and about 25 to about 100 μg budesonide, or about 90 μg albuterol and about 40 or about 80 μg budesonide.

7. The use of any one of claims 1 to 6, wherein the albuterol and the budesonide are in the composition at a weight ratio of about 1:1 to about 3:1, or about1.1:1 to about 2.5:1, or about 1.125:1 or about 2.25:1.

8. The use of any one of claims 1 to 8, wherein the albuterol and the budesonide are in the form of particles, wherein at least 90% of the particles by volume comprise an optical diameter of about 1 μm to about 7 μm.

9. The use of claim 8, wherein the particles of albuterol comprise crystalline or micronized albuterol sulfate and the particles of budesonide comprise micronized budesonide.

10. The use of any one of claims 1 to 9, wherein the composition comprises a plurality of albuterol particles; a plurality of budesonide particles; a plurality of respirable suspending particles; and a suspension medium, wherein the plurality of albuterol particles, the plurality of budesonide particles, and the plurality of respirable suspending particles are co-suspended in the suspension medium to form a co-suspension.

11. The use of claim 10, wherein the suspension medium is a pharmaceutically acceptable propellant selected from a hydrofluoroalkane (HFA) propellant, a hydrofluoroolefins (HFO) propellant, a hydrofluorocarbon propellant (HFC), and combination thereof, optionally wherein the suspension medium is a propellant of pharmaceutical grade (1E)-1,3,3,3-Tetrafluoro-1-propene (HFO-1234ze(E)).

12. The use of claim 10 or 11, wherein:

(i) the respirable suspending particles comprise a volume median optical diameter of about 0.2 μm to about 50 μm;

(ii) the respirable suspending particles are about 1 mg/mL to about 30 mg/mL in the suspension medium;

(iii) the respirable suspending particles comprise a phospholipid, optionally wherein the phospholipid is 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC);

(iv) a weight ratio of total mass of the respirable suspending particles to total mass of the albuterol and budesonide particles is about 1.5:1 to about 200:1; or

(v) any combination of (i)-(iv).

13. Use of a composition in the manufacture of a medicament for as-needed treatment or prevention of bronchoconstriction in a subject, and/or prevention of exacerbation in a subject with asthma, wherein the composition comprises therapeutically effective

amounts of albuterol and budesonide, wherein the composition is configured to be administered via a metered dose inhaler,

wherein the composition reduces risk of severe asthma exacerbation by at least about 15% as compared to a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation.

14. The use of claim 13, wherein the subject is a human subject 12 years of age or older, and the composition is optionally configured to be administered by delivery of two metered doses from the metered dose inhaler, wherein about 180 μg albuterol and about 160 μg budesonide are delivered.

15. The use of claim 13, wherein the subject is a human subject from 4 years to 11 years of age, and the composition is configured to be administered by delivery of two metered doses from the metered dose inhaler, wherein about 180 μg albuterol and about 80 μg budesonide are delivered.

16. The use of any one of claims 13 to 15, wherein the subject is not administered greater than 6 metered doses in a 24 hour period.

17. A pharmaceutical composition deliverable from a metered dose inhaler comprising therapeutically effective amounts of albuterol and budesonide for use in treatment of asthma in a subject at risk of asthma exacerbation, wherein the treatment reduces risk of severe asthma exacerbation by at least about 15% as compared to administration of a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation.

18. A pharmaceutical composition deliverable from a metered dose inhaler comprising therapeutically effective amounts of albuterol and budesonide for use in as-needed treatment or prevention of bronchoconstriction in a subject and/or prevention of exacerbation in a subject with asthma, wherein the pharmaceutical composition reduces risk of severe asthma exacerbation by at least about 15% as compared to administration of a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation.

19. The pharmaceutical composition for use of claim 17 or 18, wherein the composition comprises a plurality of albuterol particles; a plurality of albuterol particles; a plurality of respirable suspending particles; and a suspension medium, wherein the plurality of albuterol particles, the plurality of budesonide particles, and the plurality of respirable suspending particles are co-suspended in the suspension medium to form a co-suspension,

optionally wherein:

(i) the suspension medium is a propellant of pharmaceutical grade (1E)-1,3,3,3-Tetrafluoro-1-propene (HFO-1234ze(E)); and/or

(ii) the respirable suspending particles comprise a phospholipid, optionally wherein the phospholipid is 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC).

20. The pharmaceutical composition for use of any one of claims 17 to 19, wherein a hazard ratio of the treatment as compared to administration of a composition comprising a same dose of albuterol alone is less than about 0.9; and/or wherein an annualized severe asthma exacerbation rate of the treatment is at least about 20% lower as compared to administration of a composition comprising a same dose of albuterol alone.